+Compare
HELX
ETF ticker: BATS
AS OF
Loading...
Price
Loading...
Change
Loading...
Net Assets
11.15M

HELX Franklin Genomic Advancements ETF Forecast, Technical & Fundamental Analysis

Category Health
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for HELX with price predictions
07:00 PM EST Dec 05, 2023

HELX in upward trend: price rose above 50-day moving average on November 20, 2023

HELX moved above its 50-day moving average on November 20, 2023 date and that indicates a change from a downward trend to an upward trend. In of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HELX's RSI Indicator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 03, 2023. You may want to consider a long position or call options on HELX as a result. In of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HELX just turned positive on November 03, 2023. Looking at past instances where HELX's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for HELX crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 216 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NASDAQ:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NASDAQ:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NASDAQ:IQV), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 36.89B. The market cap for tickers in the group ranges from 300.73M to 561.54B. LLY holds the highest valuation in this group at 561.54B. The lowest valued company is CDMO at 300.73M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 1%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was -7%. RCKT experienced the highest price growth at 13%, while CDNS experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -64%. For the same stocks of the ETF, the average monthly volume growth was -65% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 61
Price Growth Rating: 54
SMR Rating: 74
Profit Risk Rating: 67
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALFVY36.44N/A
N/A
Alfa-Laval AB
FFNTF0.12N/A
N/A
4Front Ventures Corp.
SCRYY2.99N/A
N/A
SCOR
STEK0.03N/A
N/A
Stemtech Corp.
DSDVY78.76N/A
N/A
DSV A S

HELX and

Correlation & Price change

A.I.dvisor tells us that HELX and IBB have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HELX and IBB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HELX
1D Price
Change %
HELX100%
+1.08%
IBB - HELX
9%
Poorly correlated
+0.78%
XBI - HELX
9%
Poorly correlated
+0.95%
IHI - HELX
-1%
Poorly correlated
+0.22%
VHT - HELX
-2%
Poorly correlated
+0.11%
XLV - HELX
-4%
Poorly correlated
+0.08%